Last 48 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -6.51 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 40.48 | — | — | — | 28.81 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +40.5% | — | — | — | — | |
| P/S Ratio | 74.64 | 81.26 | 130.59 | 72.00 | 61.78 | 230.72 | 36.30 | 89.82 | 41.30 | 26.26 | 4.89 | 7.41 | 12.10 | 56.95 | 56.36 | 44.85 | 2.59 | 151.39 | 437.58 | 117.47 | 4.21 |
| — | -64.8% | +259.8% | -19.8% | +49.6% | +778.8% | +641.6% | +1111.6% | +241.2% | -53.9% | -91.3% | -83.5% | +367.2% | -62.4% | -87.1% | -61.8% | -38.5% | -18.5% | +56070.5% | -86.1% | -64.3% | |
| P/B Ratio | 6.27 | 5.73 | 9.42 | 6.87 | 6.92 | 14.93 | — | 16.71 | — | 4.30 | 2.24 | 1.71 | 1.56 | 1.19 | 1.55 | 2.31 | 2.24 | 2.08 | 1.79 | 1.54 | 1.63 |
| — | -61.6% | — | -58.9% | — | +247.0% | — | +874.8% | — | +260.8% | +45.1% | -25.9% | -30.3% | -42.8% | -13.6% | +50.1% | +37.2% | -16.7% | -21.6% | -77.0% | -75.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.15 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 8.49 | — | — | — | 35.14 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -75.8% | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 9.50 | — | — | — | 16.53 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -42.5% | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.5% | 95.5% | -78.0% | 93.9% | 38.8% | 89.2% | 87.5% | 87.4% | 88.1% | 55.4% | 32.9% | -8.7% | -32.1% | 28.5% | 44.2% | 54.3% | 98.4% | 40.6% | -67.4% | -2288.3% | 34.4% |
| — | +7.0% | -189.1% | +7.3% | -55.9% | +61.2% | +165.7% | +1101.1% | +374.7% | +94.2% | -25.4% | -116.1% | -132.6% | -29.8% | +165.5% | +102.4% | +186.4% | +102.4% | -170.9% | +67.7% | +387.6% | |
| Operating Margin | -1166.8% | -1019.6% | -956.8% | -1242.8% | -936.8% | -1379.0% | -833.6% | -2510.0% | -877.8% | -1759.0% | -395.6% | -639.1% | -923.1% | -5819.3% | -2686.8% | -1392.9% | 25.8% | -4107.5% | -11279.9% | -3017.9% | 3.6% |
| — | +26.1% | -14.8% | +50.5% | -6.7% | +21.6% | -110.7% | -292.7% | +4.9% | +69.8% | +85.3% | +54.1% | -3679.0% | -41.7% | +76.2% | +53.8% | +619.6% | -81.6% | -13246.4% | +69.2% | +114.8% | |
| Net Margin | -1236.0% | -1178.2% | -1387.8% | -1502.9% | -666.1% | -2175.9% | -716.8% | -2784.7% | -1403.2% | -1940.4% | -506.0% | -773.3% | -1094.4% | -6366.1% | -2827.2% | -1450.3% | 6.6% | -3302.8% | -7859.4% | -2604.8% | 14.2% |
| — | +45.9% | -93.6% | +46.0% | +52.5% | -12.1% | -41.7% | -260.1% | -28.2% | +69.5% | +82.1% | +46.7% | -16619.4% | -92.8% | +64.0% | +44.3% | -53.4% | -79.8% | -9226.4% | +71.5% | +793.8% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -207.1% | -19.8% | -34.2% | -30.7% | -17.3% | -71.7% | -254.1% | -324.0% | -298.6% | -58.0% | -46.2% | -37.0% | -30.7% | -28.8% | -17.9% | -17.4% | 1.5% | -10.5% | -7.6% | -8.2% | 1.4% |
| — | +72.4% | +86.5% | +90.5% | +94.2% | -23.5% | -450.4% | -775.1% | -871.7% | -101.5% | -158.3% | -113.1% | -2125.1% | -173.1% | -136.3% | -112.5% | +9.7% | -76.7% | -108.2% | +53.5% | +566.9% | |
| ROA | -28.8% | -6.4% | -9.2% | -6.7% | -4.3% | -10.9% | -6.3% | -7.5% | -12.2% | -6.4% | -7.5% | -8.2% | -8.6% | -9.9% | -8.7% | -11.6% | 1.0% | -7.1% | -5.4% | -6.0% | 1.0% |
| — | +41.8% | -45.0% | +11.1% | +64.5% | -69.6% | +15.5% | +8.3% | -41.8% | +34.7% | +13.8% | +29.1% | -948.1% | -38.2% | -62.4% | -94.0% | -2.2% | -52.5% | -107.7% | +49.5% | +612.4% | |
| ROIC | -50.7% | -34.2% | -180.2% | -9.1% | -22.2% | — | — | — | -33.4% | -9.3% | -8.4% | -8.6% | -8.7% | -13.5% | -13.0% | -14.1% | 7.8% | -36.5% | -29.9% | -24.5% | 1.1% |
| — | — | — | — | +33.7% | — | — | — | -282.8% | +30.9% | +35.6% | +38.8% | -212.2% | +63.1% | +56.5% | +42.5% | +639.5% | +1.3% | -106.8% | +47.3% | +107.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.70 | 0.21 | 0.19 | 0.42 | 2.70 | 0.29 | — | 1.97 | — | 8.98 | 5.50 | 3.70 | 2.56 | 1.94 | 1.45 | 0.34 | 0.30 | 0.33 | 0.29 | 0.25 | 0.23 |
| — | -26.8% | — | -78.4% | — | -96.8% | — | -46.8% | — | +362.1% | +280.1% | +974.6% | +754.4% | +489.6% | +406.3% | +38.7% | +31.8% | +81.8% | +69.2% | -46.2% | -22.3% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.96 | — | — | — | 34.62 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -85.7% | — | — | — | — | |
| Current Ratio | 10.43 | 11.52 | 10.01 | 10.40 | 10.43 | 7.12 | 9.98 | 11.99 | 9.74 | 6.51 | 7.36 | 9.39 | 8.85 | 10.11 | 11.07 | 6.67 | 6.28 | 7.26 | 10.84 | 12.94 | 17.09 |
| — | +61.8% | +0.3% | -13.3% | +7.0% | +9.3% | +35.7% | +27.7% | +10.1% | -35.6% | -33.6% | +40.7% | +40.9% | +39.2% | +2.1% | -48.4% | -63.3% | -48.7% | -28.0% | +47.1% | +80.4% | |
| Quick Ratio | 10.43 | 11.52 | 10.01 | 10.40 | 10.43 | 7.12 | 9.98 | 11.99 | 9.74 | 6.51 | 7.36 | 9.27 | 8.68 | 9.88 | 10.92 | 6.56 | 6.19 | 7.20 | 10.78 | 12.94 | 17.09 |
| — | +61.8% | +0.3% | -13.3% | +7.0% | +9.3% | +35.7% | +29.4% | +12.2% | -34.1% | -32.7% | +41.3% | +40.3% | +37.3% | +1.3% | -49.3% | -63.8% | -49.2% | -28.4% | +47.1% | +80.4% | |
| Interest Coverage | -2.12 | -3.15 | -5.21 | -2.78 | -1.81 | -3.30 | -1.39 | -1.86 | -3.87 | -1.67 | -2.43 | -3.04 | -3.47 | -4.80 | -8.99 | -21.02 | 7.52 | -14.70 | -13.62 | -20.63 | 3.97 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying QURE stock.
uniQure N.V.'s current P/E is -6.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
uniQure N.V.'s current operating margin is -1166.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking uniQure N.V.'s business trajectory between earnings reports.